564 - Nirsevimab effectiveness in infants against respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) and related healthcare utilization

Co-Author(s)

• AH

  Amber Hsiao, MPH

  Senior Research Project Manager
  Division of Research Kaiser Permanente Vaccine Study Center
  Oakland, California, United States
• 

  John R. Hansen, MPH

  Group Leader Consulting
  Division of Research Kaiser Permanente Vaccine Study Center
  Oakland, California, United States
• JT

  Julius Timbol, MS

  Data Analyst
  Kaiser Permanente Vaccine Study Center
  Oakland, CA, United States
• LL

  Lauren D. Liao, PhD

  Kaiser Permanente Vaccine Study Center
  Oakland, California, United States
• BF

  Bruce Fireman, MA

  Research Scientist
  Division of Research Kaiser Permanente Vaccine Study Center
  Oakland, California, United States
• 

  Ousseny Zerbo, PhD

  Research Scientist
  Division of Research Kaiser Permanente Vaccine Study Center
  Oakland, CA, United States
• KM

  Karine Mari, MSc

  Sanofi Pasteur S.A.
  Lyon, Auvergne, France
• CR

  Christopher Rizzo, MD

  Senior Medical Director
  Sanofi
  Swiftwater, Pennsylvania, United States
• WL

  William V. La Via, MD

  Sanofi Pasteur
  Swiftwater, Pennsylvania, United States
• RI

  Ruvim Izikson, MD, MPH

  Sanofi
  Bridgewater, New Jersey, United States

Presenting Author(s)

• 

  Nicola P. Klein, MD, PhD (she/her/hers)

  Director, Kaiser Permanente Vaccine Study Center and Senior Research Scientist
  Division of Research Kaiser Permanente Vaccine Study Center
  Oakland, California, United States